<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02855073</url>
  </required_header>
  <id_info>
    <org_study_id>CBMG-ReJoinTM-CL-1.0</org_study_id>
    <nct_id>NCT02855073</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Compare ReJoinTM to Sodium Hyaluronate Injection for Knee Osteoarthritis Cartilage Defects</brief_title>
  <official_title>A Randomized, Single-blind, Parallel Group ,Phase II Clinical Trial to Compare ReJoinTM (Autologous Adipose-derived Mesenchymal Progenitor Cells)to Sodium Hyaluronate Injection for the Patients With Knee Osteoarthritis Cartilage Defects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cellular Biomedicine Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cellular Biomedicine Group Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of ReJoinTM for the Knee
      Osteoarthritis patients with Cartilage Defects comparing to Sodium Hyaluronate Injection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized,single-blind,parallel group,phase II clinical trial.

      28 subjects who are with a clinical diagnosis of knee osteoarthritis cartilage defects and
      will be randomly distributed 2:1 to the treatment group or the control group after signing
      the ICF and screening tests.The treatment will accept ReJoinTM at the first and fourth
      week,and Sodium Hyaluronate Injection at the second and third week.The control group will
      accept Sodium Hyaluronate Injection weekly ,and four injections in total.The duration of the
      therapy is 48 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>WOMAC scores</measure>
    <time_frame>48 weeks</time_frame>
    <description>WOMAC scoring will be performed 48 weeks after the first injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VAS scores</measure>
    <time_frame>0 day、8 weeks、24 weeks、36 weeks and 48 weeks</time_frame>
    <description>VAS scoring will be performed 8 weeks、24 weeks、36 weeks and 48 weeks after the first injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 scores</measure>
    <time_frame>0 day、8 weeks、24 weeks、 36 weeks and 48 weeks</time_frame>
    <description>SF-36 scoring will be performed 8 weeks、24 weeks、36 weeks and 48 weeks after the first injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outbridge scoring</measure>
    <time_frame>1 day and 24 weeks</time_frame>
    <description>Outbridge scoring will be performed 24 weeks after the first injection under arthroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP</measure>
    <time_frame>0 day、8 weeks、24 weeks、 36 weeks and 48 weeks</time_frame>
    <description>Serum CRP levels will be tested 8 weeks、24 weeks、36 weeks and 48 weeks after the first injection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Defect of Articular Cartilage</condition>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>ReJoinTM Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this Group will receive ReJoinTM injections on day 1 and day 22, and Sodium Hyaluronate injection on day 8 and day 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Hyaluronate Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects in this group will receive Sodium Hyaluronate injections on day 1, 8, 15, 22.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ReJoinTM</intervention_name>
    <description>adipose derived mesenchymal progeinitor cells</description>
    <arm_group_label>ReJoinTM Group</arm_group_label>
    <other_name>adipose derived mesenchymal progenitor cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Hyaluronate</intervention_name>
    <description>Sodium Hyaluronate Injection</description>
    <arm_group_label>Sodium Hyaluronate Group</arm_group_label>
    <other_name>Artz</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-70 years old, KOA couse ≤ 10 years

          -  Kellgren-Lawrence Ⅰ-Ⅲ

          -  VAS core ＞6， more than 4 months

          -  Signed informed consent from the subject

          -  cartilage defect 2-6cm2

        Exclusion Criteria:

          -  Pregnancy test positive.

          -  Subject infected with hepatitis C, HIV or syphilis.

          -  Subject enrolled in any other cell therapy studies within the past 30 days.

          -  Subject deemed to be not suitable for the study by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>You Wang</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>You Wang</last_name>
    <phone>+86 021-23271699</phone>
    <email>drwangyou@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai ninth people's hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2016</study_first_submitted>
  <study_first_submitted_qc>August 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2016</study_first_posted>
  <last_update_submitted>August 1, 2016</last_update_submitted>
  <last_update_submitted_qc>August 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adipose-derived mesenchymal progenitor cells</keyword>
  <keyword>Artz</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Cartilage Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

